�TomoTherapy Incorporated (NASDAQ: TOMO) announced that it will introduce the TomoDirect� discrete-angle delivery mode1 for the TomoTherapy� Hi�Art� treatment system at deuce upcoming actinotherapy oncology conferences. This innovational new engineering allows Hi�Art system users to quickly plan and deliver modern TomoTherapySM radioactivity treatments with a series of running beam paths, rather than the existing helical path. With TomoDirect, clinicians canful choose several discrete angles and the optimal transition level needful for bringing, based on specific affected role therapy goals. TomoDirect will be unveiled at the annual meetings of the European Society for Therapeutic Radiology and Oncology (ESTRO) in Gothenburg, Sweden, Sept. 14-18, 2008, and the American Society for Therapeutic Radiology and Oncology (ASTRO) in Boston, Mass., Sept. 21-25, 2008.
"We are excited around TomoDirect because it testament greatly gain the overall flexibility and efficiency of the Hi�Art treatment system," said Fred Robertson, CEO of TomoTherapy. "Along with helical TomoTherapy delivery, TomoDirect will enhance our customers' revenue-generating opportunities, and tone their ability to deliver the highest quality radiation syndrome therapy to the broadest patient population."
TomoDirect was developed as a complement to voluted TomoTherapy, with both utilizing the same binary multi-leaf collimator and CT-style gauntry technology. The choice of which modality to use for a given character will depend on the nature of the tumour volume and surrounding organs at risk. TomoDirect is expected to provide significant time nest egg in both the planning and legal transfer phases for several clinical scenarios, including whole breast irradiation and palliative treatments.
Said TomoDirect research collaborator Paul Read, M.D., Ph.D., assistant prof of Radiation Oncology, University of Virginia: "TomoDirect will expand the spectrum of external radio beam radiation therapy patients world Health Organization can be optimally treated with TomoTherapy's unique image-guided, intensity-modulated radiotherapy therapy (IG-IMRT). Now, we will induce an choice to deliver dose via two unique and complemental delivery modes, choosing whichever provides the optimal venus's curse distribution. Clearly, breast cancer patients volition benefit from TomoDirect, and other disease sites testament likely be developed for which in that location is clinical benefit."
Added research partner Prof. Guy Storme, M.D., Ph.D., film director of the Oncologic Center at UZ Brussel, Brussels, Belgium: "Certainly, with the combination of helical and direct deliveries, TomoTherapy should offer significant benefit for a majority of breast cancer treatments. It will provide the ability to choose and apply the right modality for the best intervention. Our enquiry is focussed on providing comprehensive usage guidelines as we study and validate this new mode combination."
The TomoDirect delivery mode leverages the Hi�Art treatment system's alone design, componentry and capabilities. According to TomoTherapy cofounder Thomas "Rock" Mackie, Ph.D., Hi�Art system integration facilitates a simple, consistent treatment planning and delivery process across both modes of delivery.
"TomoDirect will economic consumption all the power of the platform that makes helical TomoTherapy the gold standard in radiation therapy," said Mackie. "The remainder is that we
